RT Journal Article
SR Electronic
T1 Syndemic violence victimization, alcohol and drug use, and HIV transmission risk behavior among transgender women in India: A cross-sectional, population-based study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.07.22273584
DO 10.1101/2022.04.07.22273584
A1 Chakrapani, Venkatesan
A1 Lakshmi, P.V.M.
A1 Newman, Peter A.
A1 Kaur, Jasvir
A1 Tsai, Alexander C.
A1 Vijin, P.P.
A1 Singh, Bhawani
A1 Kumar, Pradeep
A1 Rajan, Shobini
A1 Kumar, Rajesh
YR 2022
UL http://medrxiv.org/content/early/2022/04/10/2022.04.07.22273584.abstract
AB Introduction Transgender women are disproportionately burdened by HIV. Co-occurring epidemics of adverse psychosocial exposures accelerate HIV sexual risk, including among transgender women; however, studies using additive models fail to examine synergies among psychosocial conditions that define a syndemic. We examined the impact of synergistic interactions among 4 psychosocial exposures on condomless anal sex (CAS) among a national probability sample of transgender women in India.Methods A probability-based sample of 4,607 HIV-negative transgender women completed the Indian Integrated Bio-behavioral Surveillance survey, 2014−2015. We used linear probability regression and logistic regression to assess 2-, 3-, and 4-way interactions among 4 exposures (physical and sexual violence, drug and alcohol use) on CAS.Results Overall, 27.3% reported physical and 22.3% sexual violence victimization (39.2% either physical or sexual violence), one-third (33.9%) reported frequent alcohol use and 11.5% illicit drug use. Physical violence was associated with twofold higher odds of CAS in the main effects model. Significant two- and three-way interactions were identified on both multiplicative and additive scales between physical violence and drug use; physical and sexual violence; physical violence, sexual violence, and alcohol use; and physical violence, alcohol and drug use.Conclusions Physical and sexual violence victimization, and alcohol and drug use are highly prevalent and synergistically interact to increase CAS among transgender women in India. Targeted and integrated initiatives to improve assessment of psychosocial comorbidities, to combat transphobic violence, and to provide tailored, trauma-informed alcohol and substance use treatment services may reduce HIV risk among transgender women.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Integrated Behavioural and Biological Assessment (IBBS) was primarily funded by the Government of India, Ministry of Health and Family Welfare, with complementary funding from CDC-DGHA (CDC’s Division of Global HIV/AIDS) India through FHI 360, Public Health Foundation of India, and WHO India. Dr. Chakrapani was supported in part by the Wellcome Trust/DBT India Senior Alliance fellowship (IA/CPHS/16/1/502667). Dr. Newman was supported in part by a grant from the Social Sciences and Humanities Research Council of Canada (SSHRC Partnership Grant, 895–2019-1020 [MFARR-Asia]).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IBBS study was approved by the ethics committees of NACO and participating Indian Council of Medical Research regional institutes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not Applicable I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data underlying the results presented in the study are available from Dr. Shobini Rajan, National AIDS Control Organisation (NACO), India, who can be contacted at shobini{at}naco.gov.in. Access will be granted to de-identified datasets on a case-by-case basis.